medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1
2
3
4
5

Estimating the increased transmissibility of
the B.1.1.7 strain over previously circulating
strains in England using frequencies of
GISAID sequences and the distribution of
serial intervals

6
7
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Chayada Piantham1, Kimihito Ito2*,
1
2

Graduate School of Infectious Diseases, Hokkaido University; chayada@czc.hokudai.ac.jp
Research Center for Zoonosis Control, Hokkaido University; itok@czc.hokudai.ac.jp

Abstract
The B.1.1.7 strain, a variant strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), is thought to have higher transmissibility than previously circulating strains in England. This paper
proposes a method to estimate the selective advantage of a mutant strain over previously circulating
strains using the time course of B.1.1.7 strain frequencies and the distribution of serial intervals. The
method allows instantaneous reproduction numbers of infections to change during the target period of
analysis. The proposed method, instead, assumes that the selective advantage of a mutant strain over
previously circulating strains is constant over time. Applying this method to the sequence data of SARSCoV-2 in England, the instantaneous reproduction number of the B.1.1.7 strain is estimated to be 33.7%
(with a 95% confidence interval (CI) from 33.6% to 33.9%) higher than previously circulating strains in
England, assuming that serial intervals of COVID-19 follow a lognormal distribution with a mean of 4.7
days and a standard deviation of 2.9 days. The result indicated that the control measure against B.1.1.7
strain needs to be strengthened by 33.7% from that against previously circulating strains. To get the same
control effect as before, contact rates between individuals needed to be restricted to 0.748 of the contact
rates that had been achieved by the control measure taken for previously circulating strains.

Keywords: COVID-19, B.1.1.7, selective advantage, adaptive evolution, serial interval, GISAID,
England, SARS-CoV-2, instantaneous reproduction number

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has
been rapidly evolving since its emergence in 2019. In December 2020, the Public Health England
detected a new cluster of SARS-CoV-2 viruses phylogenetically distinct from the other strains circulating
in the United Kingdom (Chand et al. 2020). These viruses belong to the lineage B.1.1.7 according to the
PANGO nomenclature (Rambaut et al. 2020b). The World Health Organization (WHO) designated them
as Variant of Concern, year 2020, month 12, variant 01 (VOC 202012/01) (World Health Organization
2020).
The B.1.1.7 strain was first detected in England in September 2020, and the numbers of infections with
this strain increased in October and November in 2020 (Chand et al. 2020). By February 2021, B.1.1.7
strain occupied 95% of the SARS-CoV-2 circulating in England (Davies et al., 2021).
Several studies have compared the transmissibility of the B.1.1.7 strain to that of previously circulating
strains. Davies et al. estimated that the reproduction number of the B.1.1.7 strain is 43â€“90% (with a 95%
credible interval of 38â€“130%) higher than preexisting strains using data from England (Davies et al.,
2021). However, different models resulted in different ranges of estimates in their multiplicative increase
in reproduction number (ğ‘…). Grabowski et al. estimated a 83â€“118% increase with a confidence interval of
71â€“140% compared to previously circulating strains in England (Grabowski et al. 2021). Volz et al.
estimated 40â€“75% increase in ğ‘… using data from England (Volz et al. 2021). Their methods use the linear
regression of log odds ratio between B.1.1.7 strains and previously circulating strains and estimate
increase in transmissibility under the assumption that ğ‘… is constant over time during the target period of
analysis. Washington et al. estimated a 35â€“45% increase using data from the United States of America
using Volzâ€™s method (Washington et al., 2021). Chen et al. estimated 49â€“65% increase in reproduction
number using data from Switzerland also under the constant ğ‘… assumption (Chen et al., 2021). Due to the
high transmissibility the B.1.1.7 strain, strong control measures such as lockdown were taken when the
strain was introduced (Davies et al., 2021). Thus, the constant ğ‘… assumption is questionable when
analyzing the increase in the reproduction number of B.1.1.7 compared to that of previously circulating
strains.
In this paper, we propose a method to estimate the selective advantage of a mutant strain over previously
circulating strains. Based on Fraserâ€™s method to estimate instantaneous reproduction numbers (Fraser
2007), our method allows reproduction numbers to change during the target period of analysis. Our
approach is also based on the Maynard Smithâ€™s model of allele frequencies in adaptive evolution, which
assumes that the selective advantage of a mutant strain over previously circulating strains is constant over
time (Maynard Smith and Haigh 1974). Applying the developed method to the sequence data in England
using the serial interval distribution of COVID-19 estimated by Nishiura et al. (Nishiura et al., 2020), we
estimate the increase in the instantaneous reproduction number of B.1.1.7 strains compare to that of
previously circulating strains in England. Based on the estimate, we discuss its implication to control
measures for COVID-19.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

69

Materials and Methods

70

Sequence data

71
72
73
74
75
76
77
78
79
80

Nucleotide sequences of SARS-CoV-2 viruses were downloaded from the GISAID EpiCoV database
(Shu & McCauley, 2017) on March 1, 2021. Nucleotide sequences of viruses detected in England were
selected and aligned to the reference amino acid sequence of the spike protein of SARS-CoV-2 virus
(YP_009724390) using DIAMOND (Buchfink et al. 2015). The aligned nucleotide sequences were
translated into amino acid sequences, then were aligned with the reference amino acid sequence using
MAFFT (Katoh et al. 2002). Amino acid sequences having either an ambiguous amino acid or more than
ten gaps were excluded from the rest of analyses. Table 1 shows amino acids on the spike protein used to
characterize B.1.1.7 strain, retrieved from the PANGO database (Rambaut et al. 2020b).

81
82
83
84
85
86
87
88
89
90
91
92
93
94
95

Table 1. Amino acids on the spike protein which are used to define B.1.1.7 strains
Position on S protein
Amino acid
69
Deletion
70
Deletion
144
Deletion
501
Tyrosine (Y)
570
Aspartic acid (D)
681
Histidine (H)
716
Isoleucine (I)
982
Alanine (A)
1118
Histidine (H)

We divided amino acid sequences into three groups based on amino acids shown in Table 1. The first
group consists of sequences having all of B.1.1.7-defining amino acids in Table 1. We call a virus in this
group a â€œB.1.1.7 strainâ€. The second group contains sequences that have none of the B.1.1.7-defining
substitutions. We call a virus in this group a â€œnon-B.1.1.7 strainâ€. The third group is a set of sequences
that have at least one but incomplete set of the B.1.1.7-defining amino acids. We call a strain in the third
group a â€œB.1.1.7-like strainâ€. Table 2 shows the number of sequences categorized into each group. Figure
1 shows the daily numbers of GISAID sequences of B.1.1.7 strains, non-B.1.1.7 strains and B.1.1.7-like
strains detected in England from September 1, 2020 to February 19, 2021. We used the number of B.1.1.7
strains and non-B.1.1.7 strains for the rest of the analyses. B.1.1.7-like strains were excluded from the
analyses, since we do not know whether they had the same transmissibility as B.1.1.7 strains or not.
These numbers are provided in Supplementary Table 1.
Table 2. Number of GISAID sequences in England from September 1, 2020 to February 19, 2021
B.1.1.7 strains Non-B.1.1.7 B.1.1.7-like
Total
71692
65840
2227
139759

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

96
97
98
99
100

Figure 1. Numbers of nucleotide sequences of B.1.1.7 strains, B.1.1.7-like strains, and non-B.1.1.7
strains in England from September 1, 2020 to February 19, 2021, based on sequences retrieved
from the GISAID database on March 1, 2020.

101

Serial interval distribution

102
103
104
105
106

The serial interval is the time from illness onset in a primary case to illness onset in a secondary case
(Nishiura et al., 2020). The method we propose in this paper uses discrete distributions of serial intervals.
Let ğ‘”(ğ‘–) denote the probability that the serial interval of a transmission is ğ‘– days. We obtained the values
of ğ‘”(ğ‘–) by discretizing the lognormal distribution of serial intervals of COVID-19 estimated by Nishiura
et al. (Nishiura et al., 2020). Thus, the probability mass function of serial intervals for ğ‘– â‰¥ 0 is given by
!"#

107

ğ‘”(ğ‘–) = )

ğ‘“(ğ‘¡)ğ‘‘ğ‘¡ ,

!

108
109

where ğ‘“(ğ‘¡) is the probability density function of a lognormal distribution with a mean of 4.7 days and a
standard deviation of 2.9 days.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

110

Model of Advantageous Selection

111
112
113
114
115
116
117
118

Let us suppose that we have a large population of viruses consisting of strains of two genotypes ğ´ and ğ‘,
of which frequency in the viral population at a calendar date ğ‘¡ are ğ‘$ (ğ‘¡) and ğ‘% (ğ‘¡), respectively. Suppose
also that genotype ğ´ is a mutant of ğ‘ that emerged at time ğ‘¡& .

119
120
121
122
123
124
125
126
127
128

129
130
131

132
133
134

We assume that a virus of genotype ğ´ generates 1 + ğ‘  times as many secondary transmissions as those of
genotype ğ‘. Then, ğ‘  can be considered as the coefficient of selective advantage in adaptive evolution. As
described in Maynard Smith and Haigh (1974), the frequency of viruses of allele ğ´ after n transmissions,
ğ‘' , satisfies the following equation:
(1 + ğ‘ )ğ‘'
1+ğ‘ 
(1)
ğ‘'"# =
=
ğ‘ .
(1 + ğ‘ )ğ‘' + (1 âˆ’ ğ‘' ) 1 + ğ‘ ğ‘' '
Maynard Smithâ€™s formulation of allele frequency can be extended using the concept of instantaneous
reproduction numbers of infectious diseases. The instantaneous reproduction number is defined as the
average number of people someone infected at time ğ‘¡ could expect to infect given that conditions remain
unchanged (Fraser 2007). Let ğ¼(ğ‘¡) be the number of infections by viruses of either genotype ğ´ or ğ‘ at
calendar time ğ‘¡ and ğ‘”(ğ‘–) be the probability mass function of serial intervals, defined in the previous
subsection. Suppose that instantaneous reproduction numbers of genotypes ğ´ and ğ‘ at calendar time ğ‘¡ are
ğ‘…$ (ğ‘¡) and ğ‘…% (ğ‘¡), respectively. Assuming that the distribution of generation time of a disease can be
approximated by the serial interval distribution, the following equations give the discrete version of
Fraserâ€™s instantaneous reproduction numbers of infections by genotype ğ´ and ğ‘ at time ğ‘¡.
ğ‘…$ (ğ‘¡)

=

ğ‘$ (ğ‘¡)ğ¼(ğ‘¡)
(
âˆ‘!)& ğ‘”(ğ‘–)ğ‘$ (ğ‘¡ âˆ’ ğ‘–)ğ¼(ğ‘¡

ğ‘…% (ğ‘¡)

=

ğ‘% (ğ‘¡)ğ¼(ğ‘¡)
âˆ‘(!)& ğ‘”(ğ‘–)ğ‘% (ğ‘¡ âˆ’ ğ‘–)ğ¼(ğ‘¡ âˆ’ ğ‘–)

âˆ’ ğ‘–)

(3)

Suppose that ğ‘”(ğ‘–) is small enough to be neglected for ğ‘– < 1 and ğ‘– > ğ‘™, then ğ‘”(ğ‘–) can be truncated and the
above formula can be treated as follows.
ğ‘…$ (ğ‘¡)

=

ğ‘$ (ğ‘¡)ğ¼(ğ‘¡)
*
âˆ‘!)# ğ‘”(ğ‘–)ğ‘$ (ğ‘¡ âˆ’ ğ‘–)ğ¼(ğ‘¡

ğ‘…% (ğ‘¡)

=

ğ‘% (ğ‘¡)ğ¼(ğ‘¡)
*
âˆ‘!)# ğ‘”(ğ‘–)ğ‘% (ğ‘¡ âˆ’ ğ‘–)ğ¼(ğ‘¡

âˆ’ ğ‘–)

(2)
(3)

âˆ’ ğ‘–)

Since a virus of genotype ğ´ generates 1 + ğ‘  times as many secondary transmissions as those of genotype
ğ‘, the following equation holds
ğ‘…$ (ğ‘¡) = (1 + ğ‘ )ğ‘…% (ğ‘¡)

135
136
137

(2)

(4)

for each calendar time ğ‘¡ â‰¥ ğ‘¡& . Next we assume that for all infections at calendar time ğ‘¡, the difference in
the number of infections at the time when previous generations infected can be regarded as considerably
small, i.e.
ğ¼(ğ‘¡ âˆ’ 1) â‰ˆ ğ¼(ğ‘¡ âˆ’ 2) â‰ˆ â‹¯ â‰ˆ ğ¼(ğ‘¡ âˆ’ ğ‘™) .

(5)

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

138
139

The frequency of genotype ğ´ in the viral population at calendar time ğ‘¡, ğ‘$ (ğ‘¡), can be modeled as follows:
ğ‘$ (ğ‘¡)ğ¼(ğ‘¡)
ğ‘$ (ğ‘¡) =
ğ‘% (ğ‘¡ )ğ¼(ğ‘¡) + ğ‘$ (ğ‘¡ )ğ¼(ğ‘¡)
=

âˆ‘*!)# ğ‘”(ğ‘–) ğ‘…$ (ğ‘¡)ğ‘$ (ğ‘¡ âˆ’ ğ‘–)ğ¼(ğ‘¡ âˆ’ ğ‘–)
âˆ‘*!)# ğ‘”(ğ‘–)ğ‘…% (ğ‘¡)ğ‘% (ğ‘¡ âˆ’ ğ‘–)ğ¼(ğ‘¡ âˆ’ ğ‘–) + âˆ‘*!)# ğ‘”(ğ‘–)ğ‘…$ (ğ‘¡)ğ‘$ (ğ‘¡ âˆ’ ğ‘–) ğ¼(ğ‘¡ âˆ’ ğ‘–)

=

âˆ‘*!)# ğ‘”(ğ‘–) (1 + ğ‘ )ğ‘…% (ğ‘¡)ğ‘$ (ğ‘¡ âˆ’ ğ‘–)
âˆ‘*!)# ğ‘”(ğ‘–)ğ‘…% (ğ‘¡)(1 âˆ’ ğ‘$ (ğ‘¡ âˆ’ ğ‘–)) + âˆ‘*!)# ğ‘”(ğ‘–)(1 + ğ‘ )ğ‘…% (ğ‘¡)ğ‘$ (ğ‘¡ âˆ’ ğ‘–)

=

âˆ‘*!)# ğ‘”(ğ‘–) (1 + ğ‘ )ğ‘$ (ğ‘¡ âˆ’ ğ‘–)
âˆ‘*!)# ğ‘”(ğ‘–)(1 âˆ’ ğ‘$ (ğ‘¡ âˆ’ ğ‘–)) + âˆ‘*!)# ğ‘”(ğ‘–)(1 + ğ‘ )ğ‘$ (ğ‘¡ âˆ’ ğ‘–)

=

âˆ‘*!)# ğ‘”(ğ‘–) (1 + ğ‘ )ğ‘$ (ğ‘¡ âˆ’ ğ‘–)
.
1 + ğ‘  âˆ‘*!)# ğ‘”(ğ‘–)ğ‘$ (ğ‘¡ âˆ’ ğ‘–)

(6)

140
141

Likelihood Function

142
143

Let ğ‘›(ğ‘¡) be the number of sequences of either genotype ğ´ or ğ‘ observed at calendar date ğ‘¡. Let ğ‘‘# , â€¦ , ğ‘‘+
be calendar dates such that ğ‘›(ğ‘‘! ) > 0 for 1 â‰¤ ğ‘— â‰¤ ğ‘˜. Suppose that we have ğ‘›$ (ğ‘‘, ) sequences of genotype

144
145
146
147

ğ´ at calendar date ğ‘‘, . Since genotype ğ´ emerged at time ğ‘¡& , ğ‘$ Dğ‘‘, E = 0 ğ‘ğ‘›ğ‘‘ ğ‘% Dğ‘‘, E = 1 for ğ‘‘, < ğ‘¡& . If
the frequency of genotype ğ´ is ğ‘& at ğ‘¡& , then the following equation gives the likelihood function of ğ‘ , ğ‘¡& ,
and ğ‘& for observing ğ‘›$ (ğ‘‘, ) sequences of genotype ğ´ at calendar date ğ‘‘, :
'-." /0'! -." /
ğ‘›Dğ‘‘, E
'!-." /
ğ¿ Gğ‘ , ğ‘¡& , ğ‘& ; ğ‘›$ Dğ‘‘, EI = J
K ğ‘$ Dğ‘‘, E
G1 âˆ’ ğ‘$ Dğ‘‘, EI
,
ğ‘›$ Dğ‘‘, E

148
149
150

(7)

for 1 â‰¤ ğ‘— â‰¤ ğ‘˜. The likelihood function of ğ‘ , ğ‘¡& , and ğ‘& for observing ğ‘›$ (ğ‘‘# ), â€¦ , ğ‘›$ (ğ‘‘+ ) sequences of
genotype ğ´ at calendar dates ğ‘‘# , â€¦ , ğ‘‘+ is given by the following formula.
+

ğ¿Dğ‘ , ğ‘¡& , ğ‘$ (ğ‘¡& ) ; ğ‘›$ (ğ‘‘# ), â€¦ , ğ‘›$ (ğ‘‘+ )E

=

L ğ¿ Gğ‘ , ğ‘¡& , ğ‘$ (ğ‘¡& ) ; ğ‘›$ Dğ‘‘, EI

(8)

,)#

151
152

Parameter estimation from sequence data

153
154
155
156
157
158

The B.1.1.7 strain was first detected in England on September 20, 2020. We assume that ğ‘¡& is this day or
someday before this day. Parameters ğ‘ , ğ‘¡& , and ğ‘& were estimated by maximizing likelihood of
observations on September 1, 2020 and later on. B.1.1.7 strains, viruses having complete subset of
B.1.1.7-difining substitutions on its spike protein were considered as genotype ğ´. The non-B.1.1.7 strains,
viruses having none of B.1.1.7-defining substitutions were considered to be genotype ğ‘. The B.1.1.7-like
strains, viruses having an incomplete set of B.1.1.7 substitutions on the spike protein, were excluded from

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

159
160
161
162
163

the analysis. We truncated the distribution of serial intervals so that ğ‘”(ğ‘–) = 0 if ğ‘– < 1 or ğ‘– > 14 and
normalized ğ‘”(ğ‘–) to ensure that âˆ‘#1
!)# ğ‘”(ğ‘–) = 1. Parameters of ğ‘ , ğ‘¡& , and ğ‘& were estimated by maximizing
the likelihood defined in Equation (8). The 95% confidence intervals of parameters were estimated by
profile likelihood (Pawitan 2013). The optimization of likelihood function was done by the nloptr
package in R (Rowan 1990; Johnson 2020).

164

Results

165
166
167
168
169
170
171
172

173
174
175
176
177
178

The selective advantage of B.1.1.7 strains over non-B.1.1.7 strains, ğ‘ , was estimated to be 0.337 with its
95% confidence intervals from 0.336 to 0.339 (Table 2). The date when a B.1.1.7 virus have emerged in
England, ğ‘¡& , was estimated to be September 20, 2020 with its 95% confidence interval from September
17, 2020 to September 20, 2020. The initial frequency of B.1.1.7 among non-B.1.1.7 and B.1.1.7 strains
at the emergence in England, ğ‘& , was estimated to be 0.00574 with its 95% confidence intervals from
0.00443 to 0.00618.
Table 2. Maximum likelihood estimations of parameters
Parameter
Estimate
95% CI
ğ‘ 
0.337
[0.336, 0.339]
ğ‘¡&
September 20, 2020
[September 17, 2020, September 20, 2020]
0.00574
[0.00443, 0.00618]
ğ‘&
Figure 2 shows the time course of the frequency of B.1.1.7 strains among all strains except B.1.1.7-like
strains detected in England from September 1, 2020 to February 19, 2021. White circles indicate daily
frequencies of B.1.1.7 strains among all strains except B.1.1.7-like strains. Solid line indicates the time
course of frequency of B.1.1.7 strains calculated using parameters estimated from the data. Dashed lines
indicate its lower and upper bounds of its 95% CI.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

179
180
181
182
183
184
185

Figure 2. Time course of the frequency of B.1.1.7 strains among all strains except B.1.1.7-like
strains detected in England from September 1, 2020 to February 19, 2021. White circles indicate
the frequency of B.1.1.7 strains among B.1.1.7 and non-B.1.1.7 strains. The nucleotide sequences
were retrieved from GISAID on March 1, 2021. Solid line indicates the time course of frequency of
B.1.1.7 strains calculated using parameters estimated from the data. Dashed lines indicate its lower
and upper bounds of its 95% CI.

186

Discussion

187
188
189
190
191
192
193
194
195
196
197

In this paper, the selective advantage of the B.1.1.7 strain over non-B.1.1.7 strains in England was
estimated to be 0.337 with a 95% CI from 0.336 to 0.339. The date of emergence of B.1.1.7 strains in
England was estimated to be September 20, 2020 with its 95% confidence interval from September 17,
2020 to September 20, 2020. The initial frequency of B.1.1.7 among all sequences except B.1.1.7-like
strains at the time of emergence in England was estimated to be 0.00574 with its 95% confidence
intervals from 0.00443 to 0.00618.
The estimated selective advantage of 0.337 indicates that the B.1.1.7 strain has 33.7% higher
instantaneous reproduction numbers than those of previously circulating strains in England. This means
that control measures for the B.1.1.7 strain needed to be strengthened by 33.7% compared to that for the
previously circulating strains. To get the same control effect as for the previously circulating strains, the

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233

control measure for the B.1.1.7 needed to restrict contact rates between individuals to 1/1.337 = 0.748
of those that had been achieved by the control measure taken for the previously circulating strains.

234

Acknowledgement

235
236
237
238
239

We gratefully acknowledge the laboratories responsible for obtaining the specimens and the laboratories
where genetic sequence data were generated and shared via the GISAID Initiative, on which this research
is based. This work was supported by CREST (grant number JPMJCR1413) from Japan Science and
Technology Agency (http://www.jst.go.jp/), and the World-leading Innovative and Smart Education
(WISE) Program (1801) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan

Our estimation method is based on the principle that the expected frequency of a mutant strain among all
strains can be determined from those in the previous generation using the serial interval distribution of
infections. The method assumes that the selective advantage of a mutant strain over previously circulating
strains is constant over time, which is based on Maynard Smithâ€™s model of allele frequencies in adaptive
evolution. Based on Fraserâ€™s method for estimating the instantaneous reproduction number, our method
allows reproduction numbers of strains to change during the target period of analysis. Thus, the proposed
method removes the assumption that the reproduction number is constant over time, which is assumed in
previous studies. Our method can estimate selective advantage of viruses in a genotype over the other
genotype without estimating the reproduction numbers of viruses of each genotype. Thus the method can
be applicable for the analysis on the selection of new variants even when strong control measures such as
lockdown were introduced during the target period of analysis. We think this is the largest contribution of
this paper to the field of molecular evolution, population genetics, and infectious disease epidemiology.
The selective advantage estimated in this study relies on the serial interval distribution, and thus the
results may change depending on the serial interval distribution used in the analysis. In this paper, we
used the serial interval distribution estimated by Nishiura et al. (Nishiura et al., 2020). The distribution is
a lognormal distribution with a mean serial interval of 4.7 days with a standard deviation of 2.9 days.
Several groups have estimated the serial intervals of SARS-CoV-2 using different datasets. Some
variations are observed among these estimated values (Rai et al. 2021). Volz et al. (Volz et al. 2021)
assumes a fixed serial interval of 6.5 days based on the results by Bi et al. (Bi et al., 2020). However, Ali
et al. have reported that the serial interval estimated using data from China before January 22, 2020 was
longer than estimates after January 22, 2020 (Ali et al., 2020). The serial interval estimated by Bi et al.
contains data before January 22, 2020 and there might be some possibility that the estimated serial
interval does not reflect the current situation. This important limitation will be removed when the serial
interval distributions is analyzed using a large dataset of COVID-19 transmissions in the world.
As of March 17, 2021, the B.1.1.7 strain has been observed in 93 countries (Rambaut, Holmes, et al.,
2020). The selective advantage of the B.1.1.7 strains over previously circulating strains in other countries
remains to be our future work. Variant strains originated in Brazil and South Africa also show higher
transmissibility than previously circulating strains (World Health Organization 2021). There is an urgent
need to estimate the selective advantage of these strains over previously circulating strains. We hope that
the methodology developed in this paper provides important information for countries in the world to
establish control measures against highly transmissible variants strains such as the B.1.1.7 strain.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

240
241

(http://www.mext.go.jp/). The funders had no role in the study design, data collection and analysis,
decision to publish, or preparation of the manuscript.

242

Conflict of Interest

243

We declare that there is no conflict of interest.

244

References

245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278

1. Ali, S. T., Wang, L., Lau, E. H. Y., Xu, X. K., Du, Z., Wu, Y., Leung, G. M., & Cowling,
B. J. (2020). Serial interval of SARS-CoV-2 was shortened over time by
nonpharmaceutical interventions. Science, 369(6507), 1106-1109.
doi:10.1126/science.abc9004
2. Bi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S. A.,
Zhang, T., Gao, W., Cheng, C., Tang, X., Wu, X., Wu, Y., Sun, B., Huang, S., Sun, Y.,
Zhang, J., Ma, T., Lessler, J., & Feng, T. (2020). Epidemiology and transmission of
COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a
retrospective cohort study. Lancet Infect Dis, 20(8), 911-919. doi:10.1016/S14733099(20)30287-5
3. Buchfink, B., Xie, C., & Huson, D. H. (2015). Fast and sensitive protein alignment using
DIAMOND. Nat Methods, 12(1), 59-60. doi:10.1038/nmeth.3176
4. Chand, M., Hopkins, S., Dabrera, G., Achison, C., Barclay, W., Ferguson, N., Volz, E.,
Loman, N., Rambaut, A., & Barrett, J. (2020). Investigation of novel SARS-COV-2
variant. Variant of Concern 202012/01 (PHE gateway number: GW-1824). Retrieved
from
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_
data/file/959438/Technical_Briefing_VOC_SH_NJL2_SH2.pdf
5. Chen, C., Nadeau, S., Topolsky, I., Manceau, M., Huisman, J. S., Jablonski, K. P.,
Fuhrmann, L., Dreifuss, D., Jahn, K., Beckmann, C., Redondo, M., Kobel, O., Noppen,
C., Risch, L., Risch, M., Wohlwend, N., Kas, S., Bodmer, T., Roloff, T., Stange, M.,
Egli, A., Eckerle, I., Denes, R., Feldkamp, M., Nissen, I., Santacroce, N., Burcklen, E.,
Aquino, C., de Gouvea, A. C., Moccia, M. D., GrÃ¼ter, S., Sykes, T., Opitz, L., White, G.,
Neff, L., Popovic, D., Patrignani, A., Tracy, J., Schlapbach, R., Dermitzakis, E. T.,
Harshman, K., Xenarios, I., Pegeot, H., Cerutti, L., Penet, D., Blin, A., Elies, M., Althaus,
C., Beisel, C., Beerenwinkel, N., Ackermann, M., & Stadler, T. (2021). Quantification of
the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland. medRxiv,
2021.2003.2005.21252520. doi:10.1101/2021.03.05.21252520
6. Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D.,
Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., Wenseleers, T.,
Gimma, A., Waites, W., Wong, K. L. M., van Zandvoort, K., Silverman, J. D., Group, C.
C.-W., Consortium, C.-G. U., Diaz-Ordaz, K., Keogh, R., Eggo, R. M., Funk, S., Jit, M.,
Atkins, K. E., & Edmunds, W. J. (2021). Estimated transmissibility and impact of SARSCoV-2 lineage B.1.1.7 in England. Science. doi:10.1126/science.abg3055

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320

7. Fraser, C. (2007). Estimating individual and household reproduction numbers in an
emerging epidemic. PLoS One, 2(8), e758. doi:10.1371/journal.pone.0000758
8. Grabowski, F., Preibisch, G., GiziÅ„ski, S., KochaÅ„czyk, M., & Lipniacki, T. (2021).
SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage
and Acquires Concerning Mutations. Viruses, 13(3), 392. Retrieved from
https://www.mdpi.com/1999-4915/13/3/392
9. Johnson, S. G. The NLopt nonlinear-optimization package. Retrieved from http://abinitio.mit.edu/nlopt
10. Katoh, K., Misawa, K., Kuma, K., & Miyata, T. (2002). MAFFT: a novel method for
rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res,
30(14), 3059-3066. doi:10.1093/nar/gkf436
11. Maynard Smith, J., & Haigh, J. (1974). The hitch-hiking effect of a favourable gene.
Genet Res, 23(1), 23-35. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/4407212
12. Nishiura, H., Linton, N. M., & Akhmetzhanov, A. R. (2020). Serial interval of novel
coronavirus (COVID-19) infections. Int J Infect Dis, 93, 284-286.
doi:10.1016/j.ijid.2020.02.060
13. Pawitan, Y. (2013). In All Likelihood: Statistical Modelling and Inference Using
Likelihood. Croydon: Oxford University Press.
14. Rai, B., Shukla, A., & Dwivedi, L. K. (2021). Estimates of serial interval for COVID-19:
A systematic review and meta-analysis. Clin Epidemiol Glob Health, 9, 157-161.
doi:10.1016/j.cegh.2020.08.007
15. Rambaut, A., Holmes, E. C., O'Toole, A., Hill, V., McCrone, J. T., Ruis, C., du Plessis,
L., & Pybus, O. G. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages
to assist genomic epidemiology. Nat Microbiol, 5(11), 1403-1407. doi:10.1038/s41564020-0770-5
16. Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., Carabelli, A., Connor, T.,
Peacock, T., Robertson, D. L., & Volz, E. (2020, 5 February 2021). Preliminary genomic
characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of
spike mutations. Retrieved from https://virological.org/t/preliminary-genomiccharacterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-ofspike-mutations/563
17. Rowan, T. (1990). Functional Stability Analysis of Numerical Algorithms. (Ph.D. Thesis).
University of Texas, Austin.
18. Shu, Y., & McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data from vision to reality. Euro Surveill, 22(13). doi:10.2807/15607917.ES.2017.22.13.30494
19. Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W.
R., Laydon, D. J., Dabrera, G., Oâ€™Toole, Ã., Amato, R., Ragonnet-Cronin, M., Harrison,
I., Jackson, B., Ariani, C. V., Boyd, O., Loman, N. J., McCrone, J. T., GonÃ§alves, S.,
Jorgensen, D., Myers, R., Hill, V., Jackson, D. K., Gaythorpe, K., Groves, N., Sillitoe, J.,
Kwiatkowski, D. P., Flaxman, S., Ratmann, O., Bhatt, S., Hopkins, S., Gandy, A.,
Rambaut, A., & Ferguson, N. M. (2021). Transmission of SARS-CoV-2 Lineage B.1.1.7

medRxiv preprint doi: https://doi.org/10.1101/2021.03.17.21253775; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339

in England: Insights from linking epidemiological and genetic data. medRxiv,
2020.2012.2030.20249034. doi:10.1101/2020.12.30.20249034
20. Washington, N. L., Gangavarapu, K., Zeller, M., Bolze, A., Cirulli, E. T., Schiabor
Barrett, K. M., Larsen, B. B., Anderson, C., White, S., Cassens, T., Jacobs, S., Levan, G.,
Nguyen, J., Ramirez, J. M., Rivera-Garcia, C., Sandoval, E., Wang, X., Wong, D.,
Spencer, E., Robles-Sikisaka, R., Kurzban, E., Hughes, L. D., Deng, X., Wang, C.,
Servellita, V., Valentine, H., De Hoff, P., Seaver, P., Sathe, S., Gietzen, K., Sickler, B.,
Antico, J., Hoon, K., Liu, J., Harding, A., Bakhtar, O., Basler, T., Austin, B., Isaksson,
M., Febbo, P., Becker, D., Laurent, M., McDonald, E., Yeo, G. W., Knight, R., Laurent,
L. C., de Feo, E., Worobey, M., Chiu, C., Suchard, M. A., Lu, J. T., Lee, W., &
Andersen, K. G. (2021). Genomic epidemiology identifies emergence and rapid
transmission of SARS-CoV-2 B.1.1.7 in the United States. medRxiv.
doi:10.1101/2021.02.06.21251159
21. World Health Organization. (2020). SARS-CoV-2 Variants. Disease Outbreak News.
Retrieved from https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/
22. World Health Organization. (2021). COVID-19 Weekly Epidemiological Update.
Retrieved from https://www.who.int/publications/m/item/weekly-epidemiologicalupdate---9-february-2021

